Welcome to our dedicated page for GLAUKOS SEC filings (Ticker: GKOS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Glaukos Corporation filings document the regulatory record for an ophthalmic pharmaceutical and medical technology company with common stock listed on the New York Stock Exchange under GKOS. Recent Form 8-K reports furnish quarterly and annual financial results, preliminary net sales information, supplemental business summaries, and Regulation FD investor presentations.
The company’s proxy materials provide governance and executive-compensation disclosures, including equity-award and pay-versus-performance information. These filings also identify Glaukos as a Delaware corporation and frame disclosure around its glaucoma, corneal-disorder, and retinal-disease therapies, commercial products, risk disclosures, and public-company reporting obligations.
GLAUKOS Corp (GKOS) director Gilbert H. Kliman exercised stock options for 2,500 shares of common stock on 2026-08-19 at an exercise price of $25.77 per share. The resulting 2,500 common shares were then sold the same day at $190.00 per share. After the exercise, Kliman continued to hold stock options for 12,500 shares, and his equity awards also include 2,501 restricted stock units that are unvested or deferred.
GLAUKOS Corp (GKOS) is the issuer for a planned resale of its common stock under Rule 144 by shareholder Gilbert H. Kliman. The notice covers the potential sale of 2,500 shares of Glaukos common stock through Fidelity Brokerage Services LLC on or after 08/19/2026 on the NYSE.
The shares to be sold are tied to a stock option exercise for cash, with an aggregate market value listed as $475,000.00. Fidelity signed the notice as attorney-in-fact for Kliman.
GLAUKOS Corp president and COO Joseph E. Gilliam reported multiple option exercises and related stock sales for GKOS on 2026-08-11. He exercised options covering 60,000 shares of Common Stock and acquired an equal number of shares, then sold 60,000 Common shares in two open-market transactions at weighted average prices of $178.89 and $180.49 per share. He also continues to hold 41,983 restricted stock units and 225 stock units from the Employee Stock Purchase Plan, which remain unvested or undelivered.
Glaukos Corp senior vice president and chief financial officer Alex R. Thurman reported an options exercise and same-day sale of common stock. On August 7, 2026, he exercised stock options for 20,000 shares of common stock at an exercise price of $33.81 per share and acquired those shares, then sold 20,000 shares of common stock at a weighted average price of $180.13 per share in a sale in open market or private transactions. The option exercises and sale were effected pursuant to a Rule 10b5-1 trading plan adopted on December 15, 2025. Following these transactions, his reported holdings include 5,230 restricted stock units that have not yet vested or been delivered and 225 stock units purchased through the Employee Stock Purchase Plan.
Glaukos Corporation insider Alex R. Thurman has filed to sell common stock. The filing lists a proposed sale of 20,000 common shares, related to a stock option exercise, with an aggregate market value of $3,602,674.21 as of August 7, 2026, when 58,983,937 shares were outstanding. Recent activity over the prior three months included three sales of 10,000 shares each, for proceeds of $1,500,000.00, $1,550,000.00, and $1,600,000.00.
Glaukos Corp director Leana Wen sold 525 shares of common stock on July 31, 2026 at $167.63 per share in a sale described as an open-market or private transaction. After the sale, she reports holding 21,092 shares, including 2,501 restricted stock units that are unvested or with deferred delivery. The transaction was not reported as made under a Rule 10b5-1 trading plan.
Glaukos Corporation describes a growth strategy as a hybrid pharmaceutical-device company focused on chronic eye diseases. The company highlights 12 commercialized products and 13 disclosed pipeline programs spanning interventional glaucoma, keratoconus, eyelid disease and retinal disorders.
Key glaucoma offerings include iDose TR, a long-duration travoprost implant and the first glaucoma procedural pharmaceutical FDA-approved for re-administration, and iStent infinite for advanced glaucoma. In keratoconus, Glaukos markets Photrexa and Epioxa, the first FDA-approved epithelium-on treatment, and is advancing next-generation iLink and other programs alongside eyelid and retina platforms.
The company reports 2025 net sales of $507 million, up from $283 million in 2022, with 30% 2025 topline growth, a 20% 10-year revenue CAGR and $900 million invested in R&D since 2018. 2026 sales guidance midpoint is $690 million, 2Q 2026 adjusted gross margin is 85%, and cash and equivalents total $289 million with no debt, supported by operations in 17 countries.
Glaukos Corporation has a notice of proposed sale under Form 144 by Leana Wen covering 525 shares of common stock, with an aggregate market value of $88,005.75, expected around July 31, 2026. These shares stem from restricted stock vesting on May 30, 2025 and are classified as compensation. Over the prior three months, Wen sold 1,700 common shares on May 1, 2026 for an aggregate value of $247,095.17.
Glaukos Corporation reported 50% year‑over‑year net sales growth for the quarter ended June 30, 2026, with net sales of $185.6 million versus $124.1 million, and six‑month net sales of $336.2 million versus $230.8 million. Gross margin improved to 82% in Q2 from 78%, helped by higher‑priced iDose TR glaucoma implants and growing Epioxa corneal therapy sales.
Operating expenses rose 41% to $168.9 million, reflecting expanded commercial infrastructure, R&D spending and higher stock‑based compensation, resulting in a Q2 net loss of $18.4 million and a six‑month net loss of $38.2 million. The company held $289.3 million in cash, cash equivalents, short‑term investments and restricted cash, alongside an accumulated deficit of $971.3 million.
Growth was led by U.S. glaucoma revenue (up 64%) and corneal health revenue (up 48%), plus double‑digit international glaucoma growth aided by foreign‑exchange tailwinds. Important updates included a permanent HCPCS J‑code (J2789) for Epioxa effective July 1, 2026, proposed Medicare coverage determinations for iDose TR, and an ongoing commercial transition from Photrexa to Epioxa.